Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Silence Therapeutics plc (Silence Therapeutics) is a clinical-stage biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid to treat hematology, cardiovascular disease, and rare diseases. The company's pipeline products include Zerlasiran (SLN360) which treats cardiovascular disease; Divesiran (SLN124) for polycythemia vera and multiple hematologic conditions; SLN548 targets complement-mediated diseases; and SLN312. It utilizes mRNAi GOLD platform to provide liver cell targeting technology and target selection and screening process to improve the stability and efficacy of siRNA molecules. The company has operations in Germany, the US and the UK. Silence Therapeutics is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
72 Hammersmith Road, London, England, W148TH
Website
www.silence-therapeutics.com
No of Employees
88
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SLNCF (OTC)
Revenue (2024)
$559,000
-98.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-95.6%
(2024 vs 2023)
Market Cap*
$841.1M
Net Profit Margin (2024)
XYZ
-15,034.5%
(2024 vs 2023)
* As of and is in US$
Silence Therapeutics Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Zerlasiran (SLN360): Cardiovascular Disease |
| Divesiran (SLN124): |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Silence Therapeutics Plc | Novartis Pharmaceuticals UK Ltd | ValiRx Plc | Alnylam UK Ltd | Sareum Holdings Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | London | London | Nottingham | Maidenhead | Cambridge |
| State/Province | England | England | England | Berkshire | - |
| No. of Employees | 88 | 1,330 | 7 | - | 5 |
| Entity Type | Public | Private | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Iain Gladstone Ross | Chief Executive Officer - Interim; Chairman | Executive Board | 2025 | 72 |
| Rhonda Hellums | Secretary; Director; Chief Financial Officer; Executive Vice President | Executive Board | 2025 | 55 |
| Curtis Rambaran, MD | Chief Medical Officer | Senior Management | 2023 | - |
| Marie Wikstrom Lindholm, PhD | Chief Scientific Officer | Senior Management | 2023 | - |
| Barbara Ruskin, PhD | Senior Vice President; Chief - Intellectual Property and Innovation Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer